Tag: FGFR2

Background: Ameloblastoma imposes significant morbidity and high-recurrence rates following surgery and radiation therapy. Although 89% of cases harbor oncogenic mutations, the role of targeted therapy is undefined. Case: We describe a case of a 40-year-old male with multiply recurrent, locally invasive ameloblastoma of the posterior maxillary ridge. The tumor was…

Helsinn Group is expanding its global research and development capacity with the launch of a new dedicated hub in the U.S. The new R&D facility is a product of Helsinn’s new licensing deal with BridgeBio and will operate under Helsinn Therapeutics (U.S.). It will be instrumental in furthering the company’s projected increase in clinical activities to…

Variant #0000255165 (NC_000010.10:g.123278248A>G, FGFR2(NM_000141.4):c.939+1245T>C) Chromosome 10 Allele Unknown Affects function (as reported) Probably does not affect function Affects function (by curator) Not classified Classification method – Clinical classification likely benign DNA change (genomic) (Relative to hg19 / GRCh37) g.123278248A>G DNA change (hg38) g.121518734A>G Published as FGFR2(NM_022970.3):c.1035T>C (p.Y345=) ISCN – DB-ID FGFR2_000119 Variant remarks VKGL data sharing initiative Nederland Reference – ClinVar ID – dbSNP ID – Origin CLASSIFICATION record Segregation –…

Cogent Biosciences, Inc. Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress Building a portfolio of discovery stage programs, creating potential best-in-class small molecule kinase inhibitors for genetically defined oncology indications and rare diseases Ended 1Q 2022 with $191.0 million in cash, sufficient…

The first patient has been dosed in the phase 1 KN-4802 trial (NCT05242822) examining the safety, tolerability, and preliminary efficacy of KIN-3248, a next-generation pan-FGFR inhibitor, in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations, according to a press release from Kinnate Biopharma Inc.1 KIN-3248 is an…

Treatment options for intrahepatic cholangiocarcinoma (ICC) are limited and the prognosis is usually poor after conventional chemotherapy. A variety of selective small-molecule FGFR1-3 kinase inhibitors are clinically effective, and the FDA has also approved the FGFR inhibitors pemigatinib and infigratinib for patients with ICC who have failed standard therapy and…

The first patient has received a dose of a novel drug candidate in an early-phase trial investigating the preliminary tolerability and proper dosage of the treatment in a group of patients with advanced solid tumors that harbor the FGFR2 and/or FGFR3 gene alterations, according to a press release. “With the…

This website uses cookies to ensure the best experience. By continuing, you agree to our privacy policy. × Product successfully added to quote! × There are items in your quote. Brand: Reference GTX10647 Brand GeneTex Application IHC-PWB Storage Conditions Store as concentrated solution. Centrifuge briefly prior to opening vial. For…

FGFR inhibitors are approved for the treatment of advanced cholangiocarcinoma harboring FGFR2 fusions. However, the response rate is moderate, and resistance emerges rapidly due to acquired secondary FGFR2 mutations or due to other less-defined mechanisms. Here, we conducted high-throughput combination drug screens, biochemical analysis, and therapeutic studies using patient-derived models…

Cholangiocarcinoma, or bile duct most cancers, is lethal even when caught early. The 5-year survival rate amongst these identified early is 17% to 25%; for many sufferers, the speed is under 10%. Experts say the important thing to bettering these dismal statistics is to give attention to the various genetic…

W Reardon, R M Winter, P Rutland, L J Pulleyn, B M Jones, S Malcolm Nature Genetics 1994, 8 (1): 98-103 7987400 Crouzon syndrome is an autosomal dominant condition causing premature fusion of the cranial sutures (craniosynostosis) and maps to chromosome 10q25-q26. We now present evidence that mutations in the…

Despite treatment advancements and Food and Drug Administration (FDA) approvals of drugs in the cholangiocarcinoma (a type of bile duct cancer) space in recent years, there are still many patients with this disease who are not eligible for targeted therapies as a first treatment option, highlighting a significant need for…

Abstract We report a second patient with tracheal sleeve associated with an FGFR2 p.Glu565Ala mutation. This report describes a 30-week gestation male infant with Pfeiffer syndrome (PS) who died in the neonatal period with upper respiratory obstruction with three failed attempts at intubation before the onset of subcutaneous emphysema. The…

Lugano, Switzerland and Palo Alto, CA – Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, announced an…

This article was originally published here Biol Open. 2022 Mar 15;11(3):bio058534. doi: 10.1242/bio.058534. Epub 2022 Mar 3. ABSTRACT The role and underlying mechanisms of DNA methylation in osteogenesis/chondrogenesis remain poorly understood. We here reveal DNA methyltransferase 1 (DNMT1), which is responsible for copying DNA methylation onto the newly synthesized DNA…

Intrahepatic cholangiocarcinoma (iCCA) has emerged as a promising candidate for precision medicine, especially in the case of activating FGFR2 gene fusions. In addition to fusions, a considerable fraction of iCCA patients reveals FGFR2 mutations, which might lead to uncontrolled activation of the FGFR2 pathway but are mostly of unknown functional…

Erdafitinib demonstrated durable activity in patients with locally advanced or metastatic urothelial carcinoma with specific FGFR alterations, according to updated results from the BLC2001 trial published in The Lancet Oncology.1 The phase 2 BLC2001 trial (ClinicalTrials.gov Identifier: NCT02365597) was designed to investigate erdafitinib in patients with locally advanced and unresectable…

Stem cell-based therapies offer significant potential for treating disease or injury through the regeneration of damaged tissues. Among the various stem cells available, mesenchymal stem cells (MSCs) are garnering considerable interest because of their availability, ease of isolation, and multipotency. Importantly, under appropriate culture conditions, MSCs can be selectively induced…

NEW YORK – Innovent this week said that pemigatinib (Pemazyre) was approved in Hong Kong as a treatment for locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. The approval was based on the Phase II FIGHT-202 study, which showed a 37 percent response rate for cholangiocarcinoma patients treated…

Basel, Switzerland, January 24, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with cancer and infectious diseases, announced today that updated interim results from cohort 2 of the phase 2 study FIDES-01 (Fibroblast growth factor Inhibition with DErazantinib in Solid tumors)…

The patterned array of basal, intermediate and superficial cells in the urothelium of the mature ureter arises from uncommitted epithelial progenitors of the distal ureteric bud. Urothelial development requires signaling input from surrounding mesenchymal cells, which, in turn, depend on cues from the epithelial primordium to form a layered fibro-muscular…

Achieved important Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) milestones Added new clinical candidate BAL0891 to oncology pipeline and advanced clinical programs with derazantinib and lisavanbulin Basel, January 06, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases…

Doses first patient in first-in-human trial of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor Selects 70 mg once-daily dose for RLY-4008 andinitiates expansion cohorts in patients with FGFR2-altered solid tumors, including cholangiocarcinoma and breast cancer CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision…

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

NEW YORK –  SkylineDx said this week that it has received a capital investment of undisclosed amount from US-based investment and advisory firm Novalis LifeSciences and from Netherlands-based Van Herk Investments. SkylineDx noted it is at a “critical growth stage,” with its first products introduced in the US. Its dermatology…

dbo:abstract Pemigatinib (INN), sold under the brand name Pemazyre, is a medication for the treatment of adults with previously treated, unresectable locally advanced or metastatic bile duct cancer (cholangiocarcinoma) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. Pemigatinib works by…

1 0q26 FGFR2 Break Apart FISH Probe Kit For Research Use Only Not for Use in Diagnostic Procedures 0q26 FGFR2 Break Apart FISH Probe Kit 09N /R2 Key to Symbols Used 09N /R2 Reference Number Lot Number Global Trade Item Number Centromere D0S294 0q26. Region FGFR2 5 ATE SHGC-529 Telomere…

Recent genomic profiling studies revealed that approximately 40% of patients with biliary tract cancers harbor actionable genomic mutations. The advances in the understanding and characterization of biliary tract cancers (BTCs), particularly intrahepatic cholangiocarcinoma (iCCA), and genomic profiling over the past decade have led to a rapid expansion of available treatment…

NEW YORK – At the European Society for Medical Oncology Congress this week, precision oncology assay developer Lucence presented data that demonstrated its amplicon-based LiquidHallmark assay could be used to personalize care for people with advanced urothelial carcinoma. LiquidHallmark is a laboratory-developed test based on the company’s AmpliMark next-generation sequencing platform…

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

INTRODUCTION The development of novel cancer therapies requires knowledge of specific biological pathways to target individual tumors and eradicate cancer cells. Toward this goal, the landscape of genetic vulnerabilities of cancer, or the cancer dependency map, is being systematically profiled. Using RNA interference (RNAi) loss-of-function screens, Marcotte et al. (1),…

As far as I can find, there is only one tutorial about loading Seurat objects into WGCNA (ucdavis-bioinformatics-training.github.io/2019-single-cell-RNA-sequencing-Workshop-UCD_UCSF/scrnaseq_analysis/scRNA_Workshop-PART6.html). I am really new to programming so it’s probably just my inexperience, but I am not sure how to load my Seurat object into a format that works with WGCNA’s tutorials (horvath.genetics.ucla.edu/html/CoexpressionNetwork/Rpackages/WGCNA/Tutorials/)….